Fiore Cannabis Ltd.

OTC: FIORF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Kelowna, BCReports USD

#763 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH —DQ —GM —SS 28

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), listing tenure · ↓ market scale, disclosure history

Methodology →

Revenue TTM

$1.9M

Rev growth YoY (TTM)

-4.0%

Net income (FY)

-$7.1M

Employees

—

Market cap

$2.0k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.5M3.1M CAD2021

Net income-$7.1M-8.8M CAD2021

Operating income-$4.6M-5.7M CAD2021

Total assets$13.8M17.4M CAD2021

Liabilities$14.0M17.8M CAD2021

Equity-$269.0k-341.0k CAD2021

Revenue trend

FY2016 – FY2021 · USD

$290.0k

FY16

FY17

$1.1M

FY18

$1.7M

FY19

$2.5M

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Fiore Cannabis Ltd. booked $2.5M in FY2021 revenue, growing 47% year over year — faster than most Healthcare companies we track, at a -280.9% net margin.

Peers · Healthcare

iBX Group, Inc.——Calithera Biosciences, Inc.——Dermisonics, Inc.——Evelo Biosciences, Inc.——

Key facts

CEOErik Anderson

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersKelowna, BC

ExchangeOTC: FIORF

Employees—

IPO date2015-09-01

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.